Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
Tyra Biosciences (Nasdaq: TYRA) announced it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to present interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). The data will be presented at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain. Dr. Gary Steinberg from Rush University Medical Center will join TYRA's management team for the presentation and Q&A. The webcast will be accessible through TYRA's investor relations website, with telephone participation available through pre-registration.
Tyra Biosciences (Nasdaq: TYRA) ha annunciato che ospiterà una conference call e un webcast il 25 ottobre 2024 alle 8:00 ET per presentare i risultati clinici intermedi di TYRA-300 dallo studio di Fase 1/2 SURF301 nel cancro uroteliale metastatico (mUC). I dati saranno presentati al 36° Simposio EORTC-NCI-AACR a Barcellona, Spagna. Il Dr. Gary Steinberg del Rush University Medical Center si unirà al team di gestione di TYRA per la presentazione e il Q&A. Il webcast sarà accessibile attraverso il sito web delle relazioni con gli investitori di TYRA, con partecipazione telefonica disponibile previa registrazione.
Tyra Biosciences (Nasdaq: TYRA) anunció que llevará a cabo una conferencia telefónica y un webcast el 25 de octubre de 2024 a las 8:00 am ET para presentar los resultados clínicos intermedios de TYRA-300 del estudio SURF301 de Fase 1/2 en cáncer urotelial metastásico (mUC). Los datos se presentarán en el 36º Simposio EORTC-NCI-AACR en Barcelona, España. El Dr. Gary Steinberg del Rush University Medical Center se unirá al equipo de gestión de TYRA para la presentación y la sesión de preguntas y respuestas. El webcast será accesible a través del sitio web de relaciones con inversores de TYRA, con participación telefónica disponible mediante preinscripción.
Tyra Biosciences (Nasdaq: TYRA)는 2024년 10월 25일 오전 8시 ET에 전이성 요로 상피암(mUC)에 대한 SURF301 1/2상 연구에서 TYRA-300의 중간 임상 결과를 발표하는 컨퍼런스 콜 및 웹캐스트를 개최한다고 발표했습니다. 데이터는 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 심포지엄에서 발표될 예정입니다. Rush University Medical Center의 Gary Steinberg 박사가 TYRA의 경영진과 함께 발표 및 질의응답에 참석합니다. 웹캐스트는 TYRA의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 전화 참여는 사전 등록을 통해 가능합니다.
Tyra Biosciences (Nasdaq: TYRA) a annoncé qu'il organisera une conférence téléphonique et un webcast le 25 octobre 2024 à 8h00 ET pour présenter les résultats cliniques intermédiaires de TYRA-300 issus de l'étude de Phase 1/2 SURF301 sur le cancer urotélial métastatique (mUC). Les données seront présentées lors du 36e Symposium EORTC-NCI-AACR à Barcelone, Espagne. Dr. Gary Steinberg du Rush University Medical Center rejoindra l'équipe de direction de TYRA pour la présentation et la séance de questions-réponses. Le webcast sera accessible via le site web des relations investisseurs de TYRA, avec une participation téléphonique disponible sur pré-inscription.
Tyra Biosciences (Nasdaq: TYRA) gab bekannt, dass am 25. Oktober 2024 um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um die interimistischen klinischen Ergebnisse von TYRA-300 aus der SURF301 Phase 1/2-Studie bei metastasiertem Urothelkarzinom (mUC) vorzustellen. Die Daten werden auf dem 36. EORTC-NCI-AACR Symposium in Barcelona, Spanien, präsentiert. Dr. Gary Steinberg vom Rush University Medical Center wird dem Management-Team von TYRA für die Präsentation und die Fragerunde angehören. Der Webcast wird über die Investor-Relations-Website von TYRA zugänglich sein, wobei eine telefonische Teilnahme nach vorheriger Registrierung möglich ist.
- None.
- None.
Gary Steinberg, MD, Professor of Urology, Department of Urology, Rush University Medical Center, will be joining members of TYRA's management team on the call and will be available during Q&A.
Conference Call Information
TYRA is hosting a conference call and webcast on October 25, 2024, at 8am ET to review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at https://ir.tyra.bio. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-interim-clinical-data-of-tyra-300-from-surf301-phase-12-study-on-october-25-2024-at-8am-et-302285111.html
SOURCE Tyra Biosciences
FAQ
When will Tyra Biosciences (TYRA) present TYRA-300 interim clinical data from SURF301 study?
What is the focus of TYRA-300 SURF301 Phase 1/2 study?
Where will Tyra Biosciences (TYRA) present the TYRA-300 clinical data?
